Order Article Reprints

Alicandro G, Daccò V, Cariani L, Rosazza C, Sciarrabba CS, Ferraro F, Lanfranchi C, Medino P, Girelli D, Colombo C. Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies. Biomedicines. 2022; 10(8):1998. https://doi.org/10.3390/biomedicines10081998

Alicandro, Gianfranco, Valeria Daccò, Lisa Cariani, Chiara Rosazza, Calogero Sathya Sciarrabba, Federica Ferraro, Chiara Lanfranchi, Paola Medino, Daniela Girelli, and Carla Colombo. 2022. "Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies" Biomedicines 10, no. 8: 1998. https://doi.org/10.3390/biomedicines10081998

Alicandro, G., Daccò, V., Cariani, L., Rosazza, C., Sciarrabba, C. S., Ferraro, F., Lanfranchi, C., Medino, P., Girelli, D., & Colombo, C. (2022). Immunogenicity of BNT162b2 mRNA-Based Vaccine against SARS-CoV-2 in People with Cystic Fibrosis According to Disease Characteristics and Maintenance Therapies. Biomedicines, 10(8), 1998. https://doi.org/10.3390/biomedicines10081998